Asahi Kasei Pharma Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Asahi Kasei Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012207
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company’s portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescription drugs are used for the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome and lupus nephritis, and difficulty in urination. Asahi Kasei Pharma offers assay kits that determine glycemic control and detect prediabetes. The company’s pipeline includes candidates for acute exacerbation of idiopathic pulmonary fibrosis; chemotherapy-induced peripheral neuropathy; osteoporosis with high risk of fracture; Lupus nephritis and nephrotic syndrome; and for severe sepsis with coagulopathy. It manufactures pharmaceuticals and diagnostic kits at its manufacturing plants in Shizuoka, and Nagoya in Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.

Asahi Kasei Pharma Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Evotec Enters into Agreement with Asahi Kasei Pharma 10
Orion Enters into Agreement with Asahi Kasei Pharma 11
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 12
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 15
Licensing Agreements 16
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 16
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 17
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 18
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 19
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 20
Acquisition 22
Asahi Kasei Pharma Acquires Remaining Stake In Artisan Pharma 22
Asahi Kasei Pharma Corp – Key Competitors 24
Asahi Kasei Pharma Corp – Key Employees 25
Asahi Kasei Pharma Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Key Facts 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Asahi Kasei Pharma Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Evotec Enters into Agreement with Asahi Kasei Pharma 10
Orion Enters into Agreement with Asahi Kasei Pharma 11
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 12
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 15
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 16
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 17
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 18
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 19
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 20
Asahi Kasei Pharma Acquires Remaining Stake In Artisan Pharma 22
Asahi Kasei Pharma Corp, Key Competitors 24
Asahi Kasei Pharma Corp, Key Employees 25
Asahi Kasei Pharma Corp, Other Locations 26
Asahi Kasei Pharma Corp, Subsidiaries 26

★海外企業調査レポート[Asahi Kasei Pharma Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • City Utilities of Springfield:企業の戦略的SWOT分析
    City Utilities of Springfield - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • PT Kideco Jaya Agung:企業の戦略・SWOT・財務情報
    PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report Summary PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Rural Bank Limited:企業の戦略・SWOT・財務分析
    Rural Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Rural Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Epcor Utilities Inc:企業の戦略的SWOT分析
    Epcor Utilities Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Berjaya Corporation Berhad:企業の戦略・SWOT・財務情報
    Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Serina Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Serina Therapeutics Inc (Serina Therapeutics) is a drug company that develops therapeutics for cancer, inflammation, pain, and metabolic disorders. The company’s pipeline product includes SER-214, SER-226, SER-228, SER-232, and other proprietary drugs. It uses proprietary technology, polyoxa …
  • Flex Ltd (FLEX):企業の財務・戦略的SWOT分析
    Flex Ltd (FLEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • bitop AG-医療機器分野:企業M&A・提携分析
    Summary Bitop AG (bitop) is a developer, manufacturer and marketer of cosmetic ingredients. The company offers extremolytes, medical devices, cosmetic ingredients and bio-stabilizer products. It offers medical devices for dermatology, allergy, cough and cold; airway diseases and dry epithelia applic …
  • Agios Pharmaceuticals Inc (AGIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • HORNBACH Holding AG & Co. KGaA:企業の戦略・SWOT・財務分析
    HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Alexander & Baldwin Inc (ALEX):企業の財務・戦略的SWOT分析
    Alexander & Baldwin Inc (ALEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sanofi SA:企業の戦略・SWOT・財務情報
    Sanofi SA - Strategy, SWOT and Corporate Finance Report Summary Sanofi SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • MISC Berhad:企業の戦略・SWOT・財務分析
    MISC Berhad - Strategy, SWOT and Corporate Finance Report Summary MISC Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Genel Energy Plc (GENL):石油・ガス:M&Aディール及び事業提携情報
    Summary Genel Energy Plc (Genel) is an independent upstream oil and gas company. It carries out acquisition, exploration, and production operations. It has interest in Taq Taq and Tawke in the Kurdistan region. The company develops the Miran and Bina Bawi gas fields in Zagros Fold belt in the Kurdis …
  • Empresas Copec SA (COPEC):企業の財務・戦略的SWOT分析
    Empresas Copec SA (COPEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SmithGroupJJR:企業の戦略・SWOT・財務情報
    SmithGroupJJR - Strategy, SWOT and Corporate Finance Report Summary SmithGroupJJR - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • PolyPid Ltd (POLY):製薬・医療:M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Kyoto University-製薬・医療分野:企業M&A・提携分析
    Summary Kyoto University (Kyoto) is a research university that offers educational services. The university provides multi disciplinary courses to students of Japan including medicine, engineering, law, letters, and science. It offers medical services, and diagnoses and treats various health problems …
  • Mirabilis Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Mirabilis Medical Inc (Mirabilis Medical) is a medical device company that develops a non-invasive therapeutic ultrasound platform for the treatment of uterine fibroids in women. The company offers platform that targets symptoms of uterine fibroids such as pain, abnormal bleeding, pregnancy …
  • The Nature’s Bounty Co:企業の戦略的SWOT分析
    The Nature's Bounty Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆